Matteo Levisetti - Feb 20, 2024 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Chief Medical Officer
Signature
/s/ Matteo Levisetti by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Feb 20, 2024
Transactions value $
$0
Form type
4
Date filed
2/22/2024, 04:00 PM
Previous filing
Jul 25, 2023
Next filing
Mar 8, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +25K $0.00 25K Feb 20, 2024 Common Stock 25K $3.36 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 17, 2023 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria was deemed satisfied or waived on February 20, 2024 and these shares underlying the option vested in full.